Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 1844 to 1893 of 8289 in total 
Value Type: Measured
Network Comparison Type: Divided
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Interaction Map\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
922\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
xpa-binding protein 2 (hcnp protein) (pp3898). [source:swissprot;acc:q9hcs7]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7987.95\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8300.91\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03918\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
923\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 3 subunit 8 (eif3 p110) (eif3c). [source:swissprot;acc:q99613]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4057.54\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
4457.66\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09861\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
glycogenin-1 (ec 2.4.1.186). [source:swissprot;acc:p46976]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8186.49\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8506.98\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03915\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
924\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
opioid binding protein/cell adhesion molecule precursor (obcam) (opioid-binding cell adhesion molecule) (opcml). [source:swissprot;acc:q14982]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5406.5\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
5939.42\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09857\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
syndecan-3 (synd3). [source:swissprot;acc:o75056]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
9050.12\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
9404.18\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03912\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
925\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
my016 protein. [source:sptrembl;acc:q9h3k6]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
8398.07\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8726.39\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03909\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
[pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial precursor (ec 2.7.1.99) (pyruvate dehydrogenase kinase isoform 1). [source:swissprot;acc:q15118]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5637.43\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6193.07\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09856\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
926\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
tyrosine-protein kinase frk (ec 2.7.1.112) (nuclear tyrosine protein kinase rak). [source:swissprot;acc:p42685]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8051.79\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8366.23\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03905\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
[pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial precursor (ec 2.7.1.99) (pyruvate dehydrogenase kinase isoform 2). [source:swissprot;acc:q15119]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5637.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6193.08\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09856\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
927\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
apurinic/apyrimidinic endonuclease 2; apurinic/apyrimidinic endonuclease-like 2; apex nuclease-like 2. [source:refseq;acc:nm\_014481]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8005.86\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8318.27\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03902\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
dipeptidylpeptidase 10; dipeptidyl peptidase iv-related protein 3. [source:refseq;acc:nm\_020868]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
5638.64\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.22\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.09853\vspace{3pt}}}\\\cline{1-2}\cline{4-5}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
928\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
cytochrome c oxidase assembly protein cox11, mitochondrial precursor. [source:swissprot;acc:q9y6n1]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
5638.46\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.04\vspace{3pt}}&\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
junctional adhesion molecule 1 precursor (jam) (platelet adhesion molecule 1) (pam-1) (platelet f11 receptor). [source:swissprot;acc:q9y624]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
8287.37\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8610.75\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03902\vspace{3pt}}}\\\cline{1-2}\cline{4-5}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
929\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
citrate synthase, mitochondrial precursor (ec 2.3.3.1). [source:swissprot;acc:o75390]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
8070.54\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8385.43\vspace{3pt}}&\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
surfeit locus protein 1. [source:swissprot;acc:q15526]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
5638.46\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.04\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.09853\vspace{3pt}}}\\\cline{1-2}\cline{4-5}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
930\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
dipeptidyl aminopeptidase-like protein 6 (dipeptidylpeptidase vi) (dipeptidylpeptidase 6) (dipeptidyl peptidase iv like protein) (dipeptidyl aminopeptidase-related protein) (dppx). [source:swissprot;acc:p42658]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
5638.65\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.23\vspace{3pt}}&\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
elongation factor ts, mitochondrial precursor (ef-ts) (ef-tsmt). [source:swissprot;acc:p43897]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
7928.24\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8237.48\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.039\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
931\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
acidic leucine-rich nuclear phosphoprotein 32 family member c (tumorigenic protein pp32r1). [source:swissprot;acc:o43423]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
7637.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7935.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03899\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
seprase (ec 3.4.21.-) (fibroblast activation protein alpha) (integral membrane serine protease) (170-kda melanoma membrane-bound gelatinase). [source:swissprot;acc:q12884]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5638.59\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.17\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09853\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
932\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
acidic leucine-rich nuclear phosphoprotein 32 family member a (potent heat-stable protein phosphatase 2a inhibitor i1pp2a) (hla-dr associated protein i) (phapi) (acidic nuclear phosphoprotein pp32) (cerebellar leucine rich acidic nuclear protein). [source:swissprot;acc:p39687]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7637.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7935.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03899\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
cox15 homolog isoform 2 precursor; cytochrome c oxidase subunit 15; cytochrome c oxidase assembly protein. [source:refseq;acc:nm\_004376]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5638.46\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.04\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09853\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
933\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
acidic leucine-rich nuclear phosphoprotein 32 family member d (tumorigenic protein pp32r2). [source:swissprot;acc:o95626]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7637.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7935.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03899\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
protoheme ix farnesyltransferase, mitochondrial precursor (ec 2.5.1.-) (heme o synthase). [source:swissprot;acc:q12887]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5638.46\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6194.04\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09853\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
934\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
general vesicular transport factor p115 (transcytosis associated protein) (tap) (vesicle docking protein). [source:swissprot;acc:o60763]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7637.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7935.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03899\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial precursor (ec 2.7.1.115) (branched-chain alpha-ketoacid dehydrogenase kinase) (bckdhkin) (bckd-kinase). [source:swissprot;acc:o14874]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5640\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6195.52\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0985\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
935\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
acidic leucine-rich nuclear phosphoprotein 32 family member b (phapi2 protein) (silver-stainable protein ssp29) (acidic protein rich in leucines). [source:swissprot;acc:q92688]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7637.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7935.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03899\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
neurotrimin precursor (hnt). [source:swissprot;acc:q9p121]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5413.63\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
5946.46\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09842\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
936\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
bromodomain containing 8; thyroid hormone receptor coactivating protein; skeletal muscle abundant protein. [source:refseq;acc:nm\_006696]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7637.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7935.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03899\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
nif3-like protein 1 (amyotrophic lateral sclerosis 2 chromosomal region candidate gene protein 1) (my018 protein) (mds015). [source:swissprot;acc:q9gzt8]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
5628.21\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6180.37\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09811\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
937\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
nucleobindin 1 precursor (calnuc). [source:swissprot;acc:q02818]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
5859.25\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6432.03\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09776\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
protein x 0001. [source:refseq;acc:nm\_016302]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8214.28\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8534.22\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03895\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
938\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
dna mismatch repair protein mlh1 (mutl protein homolog 1). [source:swissprot;acc:p40692]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5859.25\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6432.03\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09776\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
hiv tat specific factor 1; cofactor required for tat activation of hiv-1 transcription. [source:refseq;acc:nm\_014500]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
7751.77\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8053.37\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03891\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
939\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
mannose-6-phosphate isomerase (ec 5.3.1.8) (phosphomannose isomerase) (pmi) (phosphohexomutase). [source:swissprot;acc:p34949]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
8454.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8783.33\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0389\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
nucleobindin 2 precursor (dna-binding protein nefa). [source:swissprot;acc:p80303]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
5859.25\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6432.03\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09776\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
940\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
adenosylhomocysteinase (ec 3.3.1.1) (s-adenosyl-l-homocysteine hydrolase) (adohcyase). [source:swissprot;acc:p23526]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
5568.96\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
6113.35\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09775\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
nocturnin (ccr4 protein homolog). [source:swissprot;acc:q9uk39]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7569.42\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7863.85\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0389\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
941\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
caax prenyl protease 1 homolog (ec 3.4.24.-) (prenyl protein-specific endoprotease 1) (farnesylated-proteins converting enzyme 1) (face-1) (zinc metalloproteinase ste24 homolog). [source:swissprot;acc:o75844]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4970.21\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
5455.34\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09761\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
transcription factor ap-2 alpha (ap2-alpha) (activating enhancer- binding protein 2 alpha) (ap-2 transcription factor) (activator protein-2) (ap-2). [source:swissprot;acc:p05549]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
8020.09\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8332.09\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.0389\vspace{3pt}}}\\\cline{1-2}\cline{4-5}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
942\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
mln 64 protein (star-related lipid transfer protein 3) (stard3) (start domain-containing protein 3) (cab1 protein). [source:swissprot;acc:q14849]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
8454.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8783.33\vspace{3pt}}&\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
phosphoglycerate kinase, testis specific (ec 2.7.2.3). [source:swissprot;acc:p07205]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
6597.56\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7240.64\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09747\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
943\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
gamma enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (neural enolase) (nse) (enolase 2). [source:swissprot;acc:p09104]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
6597.98\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7241\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09746\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
transcription factor ap-2 gamma (ap2-gamma) (activating enhancer- binding protein 2 gamma) (transcription factor erf-1). [source:swissprot;acc:q92754]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8020.09\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8332.09\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0389\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
944\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
beta enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (skeletal muscle enolase) (mse) (enolase 3). [source:swissprot;acc:p13929]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6597.98\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7241\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09746\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
protocadherin fat 2 precursor (hfat2) (multiple epidermal growth factor-like domains 1). [source:swissprot;acc:q9nyq8]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8454.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
8783.33\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0389\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
945\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
alpha enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (non- neural enolase) (nne) (enolase 1) (phosphopyruvate hydratase). [source:swissprot;acc:p06733]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6597.98\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7241\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09746\vspace{3pt}}\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
cadherin-related tumor suppressor homolog precursor (fat protein homolog). [source:swissprot;acc:q14517]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
Low confidence\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
8454.45\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
8783.33\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.0389\vspace{3pt}}}\\\cline{1-2}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
946\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
mln64 n-terminal domain homolog (stard3 n-terminal like protein). [source:swissprot;acc:o95772]\vspace{3pt}}&&&&\\\cline{2-6}
&\parbox{\wcB}{\vspace{3pt}\noindent
phosphoglycerate kinase 1 (ec 2.7.2.3) (primer recognition protein 2) (prp 2). [source:swissprot;acc:p00558]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
High confidence\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
6598.37\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
7241.32\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09744\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\parbox{\wcA}{\vspace{3pt}\noindent
947\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
signal transducing adaptor molecule 1; signal transducing adaptor molecule. [source:refseq;acc:nm\_003473]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
11797.1\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
10750.2\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.09738\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/